Jakarta, CNBC Indonesia – People taking vaccines CoronaVac Sinovac almost five times more likely to have severe symptoms Covid-19 compared to those who received the Pfizer vaccine-BioNTech/Comirnaty. This was revealed in a recent study conducted in Singapore.
A team of infectious disease experts from the National Center for Infectious Diseases (NCID) and the Ministry of Health (MOH), observed the relatively lower effectiveness of the two inactivated whole virus vaccines (Sinovac and Sinopharm), against infection Covid-19 compared to vaccines mRNA (Pfizer-BioNTech and Modern).
As a result, those who concluded the vaccine Sinovac were 4.59 times more likely to experience Covid-19 severe compared to those who received the Pfizer vaccine-BioNTech. They were also 2.37 times more likely to be infected, compared with those who took the Pfizer vaccine.BioNTech.
“Individuals vaccinated with two doses of inactivated whole virus vaccine were observed to have lower protection against infection” Covid-19 compared to those vaccinated with the vaccine mRNA,” said the study published on Tuesday (12/4/2022), quoted from Channel News AsiaThursday (14/4/2022).
“Nevertheless, both vaccines mRNA and inactivated whole virus vaccines, providing adequate protection against severe symptoms Covid-19 and vaccination remains the main strategy against pandemic.”
Meanwhile, severe symptoms in the study were defined as those requiring supplementation oxygen in the hospital, admission to the intensive care unit (ICU), or death.
The findings also show that the vaccine Modern more effective in preventing severe symptoms than Pfizer-BioNTech.
Those who use Modern found to be less than half (0.42) times more likely to develop Covid-19 worse than Pfizer recipients-BioNTechand they are also less likely to become infected.
Citing a report from the United States Centers for Disease Control and Prevention (CDC USA), vaccine effectiveness Modern which is higher is likely due to the content of mRNA higher in vaccines Modern and a longer time interval between injections.
The study involved approximately 2.7 million people in Singapore aged 20 years and over who received two doses under the national vaccination programme. The data is taken for a seven-week period in 2021 from October 1 to November 21, when cases in Singapore spiked due to the Delta variant of the coronavirus.
(tfa/luc)
–
